Pathogenesis and treatment of hepatic encephalopathy based on intestinal microbiota
ZHOU Jianbo1 FU Weiqiang1 WU Xiongjian2
1.The First Clinical Medical College, Gannan Medical University, Jiangxi Province, Ganzhou 341000, China;
2.Department of Gastroenterology, the First Affiliated Hospital of Gannan Medical University, Jiangxi Province, Ganzhou 341000, China
Abstract：Hepatic encephalopathy is a common complication of liver cirrhosis. Cognitive dysfunction and abnormal signs of nervous system are the main clinical manifestations, and the fatality rate is relatively high. Currently, the pathogenesis of hepatic encephalopathy is still unclear and specific treatment is lacking. The intestinal microecosystem of patients with hepatic encephalopathy is dysfunctional, and it may induce hepatic encephalopathy by promoting the production of blood ammonia, releasing inflammatory factors, affecting the production of neurotransmitters, and reducing the synthesis of bile acids and short-chain fatty acids. Therefore, the treatment of hepatic encephalopathy based on intestinal flora has become a new entry point, including the use of probiotics, prebiotics, and antibiotics and fecal microbiota transplantation. This review summarizes the main mechanism of action of intestinal flora in hepatic encephalopathy and related treatments based on intestinal flora, in order to provide a new theoretical basis for clinical treatment of hepatic encephalopathy.
[1] Ochoa-Sanchez R，Rose CF. Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease [J]. J Clin Exp Hepatol，2018，8（3）：262-271.
[2] Marshall JC. The gut as a potential trigger of exercise-induced inflammatory responses [J]. Can J Physiol Pharmacol，1998，76（5）：479-484.
[3] Chen Z，Ruan J，Li D，et al. The Role of Intestinal Bacteria and Gut-Brain Axis in Hepatic Encephalopathy [J]. Front Cell Infect Microbiol，2020，10：595759.
[4] Liotta EM，Kimberly WT. Cerebral edema and liver disease：Classic perspectives and contemporary hypotheses on mechanism [J]. Neurosci Lett，2020，721：134818.
[5] 高婵婵，李京涛，魏海梁，等.基于TLR4/NF-κB/NLRP3信号通路探讨M1型巨噬细胞极化在肝硬化-肝性脑病发病中的研究进展[J].现代消化及介入诊疗，2020，25（10）：1321-1323.
[6] Fan Y，Li Y，Chu Y，et al. Toll-Like Receptors Recognize Intestinal Microbes in Liver Cirrhosis [J]. Front Immunol，2021，12：608498.
[7] 汤世豪，陈辉，韩国宏.肠道菌群与肝硬化肝性脑病的关系[J].临床肝胆病杂志，2019，35（5）：1109-1113.
[8] 黄晓雯，畅君雷.外周炎症对血脑屏障功能的影响及其机制研究进展[J].生命科学，2021，33（1）：7-14.
[9] Bajaj JS，Shamsaddini A，Fagan A，et al. Distinct gut microbial compositional and functional changes associated with impaired inhibitory control in patients with cirrhosis [J]. Gut Microbes，2021，13（1）：1953247.
[10] Agusti A，Hernandez-Rabaza V，Balzano T，et al. Sildenafil reduces neuroinflammation in cerebellum，restores GABAergic tone，and improves motor in-coordination in rats with hepatic encephalopathy [J]. CNS Neurosci Ther，2017，23（5）：386-394.
[11] Wen FF，Xu Z，Liu LP，et al. Effect of dopamine on intracerebral glutamate uptake ability in rats with minimal hepatic encephalopathy and the pathogenesis of minimal hepatic encephalopathy [J]. Zhonghua Gan Zang Bing Za Zhi，2018， 26（1）：48-53.
[12] El KA，Tamegart L，Draoui A，et al. Kinetic deterioration of short memory in rat with acute hepatic encephalopathy：Involvement of astroglial and neuronal dysfunctions [J]. Behav Brain Res，2019，367：201-209.
[13] Song Z，Cai Y，Lao X，et al. Taxonomic profiling and populational patterns of bacterial bile salt hydrolase（BSH）genes based on worldwide human gut microbiome [J]. Microbiome，2019，7（1）：9.
[14] Kiriyama Y，Nochi H. The Biosynthesis，Signaling，and Neurological Functions of Bile Acids [J]. Biomolecules，2019，9（6）:232.
[15] Leonel AJ，Alvarez-Leite JI. Butyrate：implications for intestinal function [J]. Curr Opin Clin Nutr Metab Care，2012， 15（5）：474-479.
[16] Juanola O，Ferrusquia-Acosta J，Garcia-Villalba R，et al. Circulating levels of butyrate are inversely related to portal hypertension，endotoxemia，and systemic inflammation in patients with cirrhosis [J]. Faseb J，2019，33（10）：11595- 11605.
[17] Silva YP，Bernardi A，Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication [J]. Front Endocrinol（Lausanne），2020，11：25.
[18] 余芳杰.乳果糖联合双歧杆菌三联活菌胶囊在轻微性肝性脑病患者中的应用效果[J].中国微生态学杂志，2020，32（8）：929-932.
[19] 柳萍飞，包健.亚临床肝性脑病患者肠道菌群和血清炎症因子水平变化及益生菌的干预作用[J].中国微生态学杂志，2020，32（2）：180-182.
[20] Cao Q，Yu CB，Yang SG，et al. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy：A meta-analysis [J]. Hepatobiliary Pancreat Dis Int，2018， 17（1）：9-16.
[21] Gluud LL，Vilstrup H，Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis [J]. Cochrane Database Syst Rev，2016，4：CD003044.
[22] Yu J，Zhang W，Zhang R，et al. Lactulose accelerates liver regeneration in rats by inducing hydrogen [J]. J Surg Res，2015，195（1）：128-135.
[23] Ruszkowski J，Witkowski JM. Lactulose：Patient-and dose- dependent prebiotic properties in humans [J]. Anaerobe，2019，59：100-106.
[24] Sharma P，Sharma BC. Management of overt hepatic encephalopathy [J]. J Clin Exp Hepatol，2015，5（Suppl 1）：S82-S87.
[25] 徐小元，丁惠国，李文刚，等.肝硬化肝性脑病诊疗指南[J].中华肝脏病杂志，2018，26（10）：721-736.
[26] Shukla S，Shukla A，Mehboob S，et al. Meta-analysis：the effects of gut flora modulation using prebiotics，probiotics and synbiotics on minimal hepatic encephalopathy [J]. Aliment Pharmacol Ther，2011，33（6）：662-671.
[27] Schulz C，Schutte K，Vilchez-Vargas R，et al. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy [J]. Dig Dis，2019，37（2）：161-169.
[28] Kimer N，Pedersen JS，Tavenier J，et al. Rifaximin has minor effects on bacterial composition，inflammation，and bacterial translocation in cirrhosis：A randomized trial [J]. J Gastroenterol Hepatol，2018，33（1）：307-314.
[29] 龚家顺，张艳翎，陈浩.利福昔明与乳果糖、拉克替醇治疗肝性脑病疗效和安全性的meta分析[J].临床荟萃，2015，30（2）：191-195.
[30] Hudson M，Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin：a review of the evidence [J]. Eur J Gastroenterol Hepatol，2019， 31（4）：434-450.
[31] Ishikawa T，Endo S，Imai M，et al. Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy [J]. Intern Med，2020，59（20）： 2465-2469.
[32] Bajaj JS，Salzman N，Acharya C，et al. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis [J]. JCI Insight，2019，4（24）：e133410.
[33] 陈斌，徐嘉蔚，彭杰，等.基于逍遥散及其拆方研究“肝病实脾法”对肝纤维化大鼠肠道菌群的影响[J].临床肝胆病杂志，2016，32（4）：657-662.
[34] 陈玲，胡晓霞，马媛媛，等.降糖药物对肠道菌群影响的研究进展[J].中国糖尿病杂志，2020，28（2）：150-152.
[35] Campion D，Giovo I，Ponzo P，et al. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis [J]. World J Hepatol，2019，11（6）：489-512.
京公网安备 11010502046598号